Gene therapy with adeno-associated virus vector 5–human factor IX in adults with hemophilia B
W Miesbach, K Meijer, M Coppens… - Blood, The Journal …, 2018 - ashpublications.org
Gene therapy for hemophilia B aims to ameliorate bleeding risk and provide endogenous
factor IX (FIX) activity/synthesis through a single treatment, eliminating the requirement for …
factor IX (FIX) activity/synthesis through a single treatment, eliminating the requirement for …
[PDF][PDF] Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B
W Miesbach, K Meijer, M Coppens, P Kampmann… - blood, 2018 - iacld.com
Gene therapy for hemophilia B aims to ameliorate bleeding risk and provide endogenous
factor IX (FIX) activity/synthesis through a single treatment, eliminating the requirement for …
factor IX (FIX) activity/synthesis through a single treatment, eliminating the requirement for …
[HTML][HTML] Gene therapy with adeno-associated virus vector 5–human factor IX in adults with hemophilia B
W Miesbach, K Meijer, M Coppens, P Kampmann… - Blood, 2018 - Elsevier
Gene therapy for hemophilia B aims to ameliorate bleeding risk and provide endogenous
factor IX (FIX) activity/synthesis through a single treatment, eliminating the requirement for …
factor IX (FIX) activity/synthesis through a single treatment, eliminating the requirement for …
Gene therapy with adeno-associated virus vector 5–human factor IX in adults with hemophilia B
W Miesbach, K Meijer, M Coppens, P Kampmann… - Blood, 2018 - cir.nii.ac.jp
抄録< jats: title> Key Points</jats: title>< jats: p> AAV5 liver-directed wild-type hFIX gene
transfer was well tolerated and clinically effective in severe and moderate-severe …
transfer was well tolerated and clinically effective in severe and moderate-severe …
Gene therapy with adeno-associated virus vector 5–human factor IX in adults with hemophilia B
W Miesbach, K Meijer, M Coppens, P Kampmann… - …, 2018 - vivantes.elsevierpure.com
Gene therapy for hemophilia B aims to ameliorate bleeding risk and provide endogenous
factor IX (FIX) activity/synthesis through a single treatment, eliminating the requirement for …
factor IX (FIX) activity/synthesis through a single treatment, eliminating the requirement for …
[PDF][PDF] Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B
W Miesbach, K Meijer, M Coppens, P Kampmann… - blood, 2018 - elabmarket.net
Gene therapy for hemophilia B aims to ameliorate bleeding risk and provide endogenous
factor IX (FIX) activity/synthesis through a single treatment, eliminating the requirement for …
factor IX (FIX) activity/synthesis through a single treatment, eliminating the requirement for …
Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B.
W Miesbach, K Meijer, M Coppens, P Kampmann… - Blood, 2017 - europepmc.org
Gene therapy for hemophilia B aims to ameliorate bleeding risk and provide endogenous
factor IX (FIX) activity/synthesis through a single treatment, eliminating the requirement for …
factor IX (FIX) activity/synthesis through a single treatment, eliminating the requirement for …
[PDF][PDF] Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B
W Miesbach, K Meijer, M Coppens, P Kampmann… - blood, 2018 - iacld.com
Gene therapy for hemophilia B aims to ameliorate bleeding risk and provide endogenous
factor IX (FIX) activity/synthesis through a single treatment, eliminating the requirement for …
factor IX (FIX) activity/synthesis through a single treatment, eliminating the requirement for …
Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B
W Miesbach, K Meijer, M Coppens, P Kampmann… - Blood, 2018 - research.regionh.dk
Hemophilia B gene therapy aims to ameliorate bleeding risk and provide endogenous factor
IX (FIX) activity/synthesis through a single treatment, eliminating the requirement for FIX …
IX (FIX) activity/synthesis through a single treatment, eliminating the requirement for FIX …
Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B
W Miesbach, K Meijer, M Coppens… - …, 2018 - researchinformation.amsterdamumc …
Hemophilia B gene therapy aims to ameliorate bleeding risk and provide endogenous factor
IX (FIX) activity/synthesis through a single treatment, eliminating the requirement for FIX …
IX (FIX) activity/synthesis through a single treatment, eliminating the requirement for FIX …